fibrinogen

H-D-Phe-Pip-Arg-pNA dihydrochloride (S-2238 dihydrochloride), a chromogenic substrate, mimics the N-terminal fragment of the A alpha chain of fibrinogen, the native substrate of thrombin. Specifically designed for thrombin detection, it is employed for quantifying antithrombin-heparin cofactor (AT-III) and is characterized by its sensitivity, accuracy, and ease of implementation.

GPRP acetate (Pefabloc FG) is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).

Fibrinogen is a heterodimeric protein that can be cleaved by thrombin. Fibrinogen is a potential marker for cardiovascular disease and plays an important role in metabolism. Its absence can cause fibrinogenemia.

γ-Fibrinogen377-395 TFA is an inhibitory peptide derived from fibrinogen, which also functions as a fibrinogen epitope. It effectively blocks microglial activation and impedes fibrin-Mac-1 interactions in vitro. Additionally, it exhibits in vivo efficacy by suppressing experimental autoimmune encephalomyelitis (EAE) in mice. This compound has applications in researching multiple sclerosis (MS) and other neuroinflammatory diseases linked to blood-brain barrier disruption and microglial activation [1].

γ-Fibrinogen377-395 is a peptide derived from fibrinogen, functioning both as an inhibitory molecule and an epitope. It inhibits microglial activation, disrupts fibrin-Mac-1 interactions in vitro, and mitigates experimental autoimmune encephalomyelitis (EAE) in murine models in vivo. This compound is relevant for research into multiple sclerosis (MS) and other neuroinflammatory disorders characterized by blood-brain barrier compromise and microglial activation [1].

Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen, a soluble plasma protein and cofactor in platelet activation, is converted to fibrin in a thrombin-catalyzed reaction.

Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin

Fibrinogen Binding Inhibitor Peptide, a synthetic dodecapeptide, represents the specific platelet receptor recognition site of the human fibrinogen g-chain (residues 400-411).

Fibrinogen γ-chain (117-133) is a selective inhibitor of intercellular adhesion molecule-1 (ICAM-1), with an IC50 of approximately 20-40 μg/mL. It can block fibrinogen-mediated adhesion of monocytes to endothelial cells and shows potential for research in thrombo-inflammatory diseases, such as atherosclerosis and organ transplant rejection.

Bovine fibrinogen (from fibrinogen) is a natural fibrinogen derived from bovine plasma. It can modulate the activation of NF-KB in endothelial cells and upregulate the expression of the inflammatory chemokine MCP-1.

Fibrinogen (from human plasma) is suitable for preparing production factor solutions.

Fibrinogen from rat plasma can be used for the preparation of growth factor solutions.

SC-52012 is a novel and potent fibrinogen receptor antagonist, an RGD mimetic, which inhibits platelet aggregation.

Sucralfate (Sucrose octasulfate–aluminum complex) is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.

Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate) , a selective, high-affinity P2Y12 receptor antagonist, suppressess fibrinogen binding to platelets and platelet adhesion and aggregation.

Arg-Gly-Glu-Ser acetate is a RGD related peptide that is a control for the RGDS activity of fibrinogen binding to activated platelets.

Arg-Gly-Asp-Ser (RGDS peptide) is a conserved tetrapeptide sequence found on fibronectin, fibrinogen α, and von Willebrand factor. It binds to integrins on the cell surface, inhibiting thrombin-induced platelet-fibrinogen interaction.

DSPE-PEG(2000)-azide is a PEGylated derivative based on 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (1,2-DSPE). This compound is utilized for attaching vascular cell adhesion molecule-1 (VCAM-1) antibodies to vesicles that encapsulate fingolimod, aiming to target the delivery of fingolimod to inflammatory vessels in mouse models simulating post-ischemic neuroinflammation. Additionally, DSPE-PEG(2000)-azide is employed to link fibrinogen mimetic peptides (FMP) to the surface of synthetic platelets used in treating uncontrollable bleeding caused by liver damage in mouse models.

Des-ethyl-carafiban (Compound 44) is an antagonist of the fibrinogen receptor, effectively inhibiting platelet aggregation induced by various agonists. It is useful for research in thrombotic diseases.

RGH-1875 (GYKI 39521) hydriodide is the hydriodide salt form of RGH-1875, which is an orally active antithrombotic agent. It prevents the reduction of fibrinogen levels and platelet counts induced by endotoxins, reduces levels of fibrin degradation products, and inhibits the enhancement of endotoxin-induced fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1875 is applicable for research on thrombotic disorders.

ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. It inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptors on platelets. ZD 2486 is applicable in research concerning diseases linked to undesirable platelet aggregation, such as acute coronary syndromes, unstable angina, acute myocardial infarction, and complications from cardiovascular interventions.

RGH-1962 is an orally active antithrombotic agent. It prevents the endotoxin-induced reduction in fibrinogen levels and platelet count, decreases fibrin degradation product levels, and inhibits the enhancement of fibrinolytic activity in an endotoxin-induced disseminated intravascular coagulation model in rabbits. RGH-1962 is applicable for research in thrombotic diseases.

GR 144053 trihydrochloride is a potent and selective GPIIb/IIIa receptor antagonist (IC50 = 20 nM). It inhibits fibrinogen-mediated platelet aggregation, used for thrombosis and antiplatelet drug discovery research.

L 366763 is an antagonist of the peptidyl fibrinogen receptor.